{"nctId":"NCT00620464","briefTitle":"A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720)","startDateStruct":{"date":"2005-05"},"conditions":["Contraception"],"count":108,"armGroups":[{"label":"Radiopaque Implanon (ro imp)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Radiopaque Implanon"]},{"label":"Implanon (imp)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Implanon (etonogestrel implant)"]}],"interventions":[{"name":"Radiopaque Implanon","otherNames":[]},{"name":"Implanon (etonogestrel implant)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At least 18 but not older than 40 years of age at the time of screening\n* Good physical and mental health\n* Regular cycles with a usual length between 24 and 35 days\n* Body mass index ≥ 18 and ≤ 29\n* Willing to give informed consent in writing\n\nExclusion Criteria:\n\n* Contraindications:\n\n  * known or suspected pregnancy\n  * active venous thromboembolic disorder (e.g. deep vein thrombosis,pulmonary embolism)\n  * presence or history of severe hepatic disease as long as liver function values have not returned to normal\n  * malignancy or pre-malignancy, if sex -steroid-influenced\n  * undiagnosed vaginal bleeding\n  * hypersensitivity to any of the components of Implanon/Radiopaque Implanon\n* Hypertension, i.e. systolic blood pressure \\>140 mmHg and/or diastolic blood pressure \\> 90 mmHg.\n* A history during pregnancy or during previous use of sex steroids of: jaundice and/or severe pruritus related to cholestasis; gallstone formation; porphyria; systemic lupus erythematosus; haemolytic uraemic syndrome; Sydenham's chorea; herpes gestationis; otosclerosis-related hearing loss\n* Present use or use during 2 months prior to the start of Implanon/Radiopaque Implanon of one of the following drugs: phenytoin, phenobarbital, primidone, carbamazepine, rifampicin, oxcarbazepine, topiramate, felbamate, ritonavir, nelfinavir, griseofulvin or the herbal remedy St John's wort.\n* Administration of investigational drugs within 2 months prior to the start of Implanon/Radiopaque Implanon","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"40 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Bioequivalence of Implanon® and Radiopaque Implanon.","description":"Bioequivalence testing was performed based on serum etonogestrel AUC0-6months, AUC0-24months, and AUC0-36months. Bioequivalence was to be concluded when the 90% confidence limits of AUC0-6months, AUC0-24months, and AUC0-36months were fully contained within the acceptance range of 0.80-1.25.\n\nAUC0-6months (Area under the curve from zero to six months).\n\nAUC0-24months (Area under the curve from zero to 24 months).\n\nAUC0-36months (Area under the curve from zero to 36 months).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2296","spread":null},{"groupId":"OG001","value":"2290","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5954","spread":null},{"groupId":"OG001","value":"6131","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7667","spread":null},{"groupId":"OG001","value":"7819","spread":null}]}]}]},{"type":"PRIMARY","title":"Bioequivalence of Implanon® and Radiopaque Implanon","description":"Bioequivalence testing was performed based on serum etonogestrel Cmax. Bioequivalence was to be concluded when the 90% confidence limits of Cmax were fully contained within the acceptance range of 0.80-1.25.\n\nCmax (pg/mL): Peak concentration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1200","spread":null},{"groupId":"OG001","value":"1145","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":56},"commonTop":["Genital haemorrhage","Vaginal haemorrhage","Implant site haematoma","Nasopharyngitis","Headache"]}}}